A study lead by Dr. Zoubeidi with a team from the Vancouver Prostate Centre and collaborators at Weill Cornell Medicine has been published online on October 26, in AACR's journal Cancer Discovery.
OncoGenex Pharmaceuticals Inc. has announced positive survival results from the final analysis of the Apatorsen Phase 2 Borealis-2™ trial in metastatic bladder cancer. Apatorsen (OGX-427) was discovered at the VPC and outlicensed to OncoGenex. The full press release is below; click here for the original article on PR Newswire (opens in new window).
VANCOUVER, BC, Canada and SHENZHEN, China - Five leading health and research organizations in British Columbia and the world’s largest genomics organization, based in China, have formed a global partnership to bring together advanced technologies and individualized therapy for cancer and other diseases.
The Terry Fox Research Institute published a news article outlining the success of the TFRI-funded teams in the 2016 Terry Fox run. The VPC team raised $40,000 between online and offline pledges, with over $23,000 raised by Dr. Gleave and over $12,000 by Dr. Black. We would like to thank all donors, volunteers and participants for making this run very successful.
The Vancouver Prostate Centre has been awarded $7.5M over 5 years towars our six-project, five-core research program titled The Terry Fox New Frontiers Program Project in Targeting the adaptive molecular landscape in castrate-resistant prostate cancer. This carries on the research performed in previous Terry Fox Program Projects, the first of which was awarded in 1998.
Prostate Cancer Canada hosted a fundraising concert event by Eric McCormack in Vancouver, on August 5 & 6. Prior to the show, Eric visited our Centre and spoke with Drs. Rennie, Boniface, Cherkasov & Ong. Click here to watch a video of this visit.
Vancouver, B.C, (June 27, 2016) – Dr. Larry Goldenberg, founding Chairman of the Canadian Men’s Health Foundation was awarded the prestigious 2016 Canadian Urological Association Lifetime Achievement Award. This honour is in recognition of Dr. Goldenberg’s outstanding leadership in research, education, pioneering treatment of prostate cancer and supportive care.
May 18, 2016, Vancouver, B.C – BGI, headquartered in China, and the Vancouver Prostate Centre (VPC) signed a memorandum of understanding to bring together advanced and cost effective sequencing, genomics and computing technologies of BGI with the world class translational cancer research and drug development program at the VPC.
New tools developed at the Vancouver Prostate Centre (VPC) are substantially advancing the possibility of offering precise, personalized therapies to effectively treat treatment-resistant prostate cancer, also known as metastatic castration-resistant prostate cancer (mCRPC).